Marketing plan design proposal of fruit pulp from Colombia to the us market for the company Fast Fruit Ltda. Pulpa de fruta

This paper explores the feasibility of internationalizing a product from a Colombian company to the U.S. market. The study is developed through the documentary research which provides a general understanding of the current situation on the food market at national and international level. In recent years, the number of exports has gradually increased due to commercial agreements between countries, supporting the internal economy to grow and changing the country's image in the world where Colombia is well-recognized because of its high quality agricultural products. At the same time, it is analyzed two internationalization methods whereby the enterprise could guide to start this process in a foreign market taking into account marketing strategies in order to implement and develop it successfully.Abstract Table of contents Introduction Objectives General Objective Specific Objectives: General statement Question Background Referential Framework United States Market Analysis Australia Market Analysis Canada Market Analysis United Kingdom Market Analysis Theoretical Framework Internationalization Marketing proposal Business Plan Plan Proposal International SWOT Analysis The main product imported by U.S Similar products: Distribution channels Economic Analysis GDP Growth rate Consumption rates Per capita income Natural resources Workforce Inflation Product demand Prices (similar products) Alliances (economic-trade) Trade policies Colombian investments in U.S.A. Marketing Marketing strategies About the product composition The advertising Customer Satisfaction Creation of value Funds and investments Relationship Marketing Advantages and Disadvantages The product itself Alliances Commercialization Projections Conclusions ReferencesPregradoProfesional en Lenguas ModernasLenguas Moderna

Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

Objectives: The objective of this study was to estimate the association between tocilizumab or corticosteroids and the risk of intubation or death in patients with coronavirus disease 19 (COVID-19) with a hyperinflammatory state according to clinical and laboratory parameters. Methods: A cohort study was performed in 60 Spanish hospitals including 778 patients with COVID-19 and clinical and laboratory data indicative of a hyperinflammatory state. Treatment was mainly with tocilizumab, an intermediate-high dose of corticosteroids (IHDC), a pulse dose of corticosteroids (PDC), combination therapy, or no treatment. Primary outcome was intubation or death; follow-up was 21 days. Propensity score-adjusted estimations using Cox regression (logistic regression if needed) were calculated. Propensity scores were used as confounders, matching variables and for the inverse probability of treatment weights (IPTWs). Results: In all, 88, 117, 78 and 151 patients treated with tocilizumab, IHDC, PDC, and combination therapy, respectively, were compared with 344 untreated patients. The primary endpoint occurred in 10 (11.4%), 27 (23.1%), 12 (15.4%), 40 (25.6%) and 69 (21.1%), respectively. The IPTW-based hazard ratios (odds ratio for combination therapy) for the primary endpoint were 0.32 (95%CI 0.22-0.47; p < 0.001) for tocilizumab, 0.82 (0.71-1.30; p 0.82) for IHDC, 0.61 (0.43-0.86; p 0.006) for PDC, and 1.17 (0.86-1.58; p 0.30) for combination therapy. Other applications of the propensity score provided similar results, but were not significant for PDC. Tocilizumab was also associated with lower hazard of death alone in IPTW analysis (0.07; 0.02-0.17; p < 0.001). Conclusions: Tocilizumab might be useful in COVID-19 patients with a hyperinflammatory state and should be prioritized for randomized trials in this situatio